NasdaqGS:VIRBiotechs
A Look At Vir Biotechnology (VIR) Valuation After New SOLSTICE Trial Data And Pipeline Updates
Why Vir Biotechnology’s latest clinical data matters for investors
Vir Biotechnology (VIR) recently reported new positive data from its SOLSTICE Phase 2 trial in chronic hepatitis delta, highlighting stronger and more sustained hepatitis delta virus RNA suppression for its tobevibart and elebsiran combination through 96 weeks.
The company also used the 44th Annual J.P. Morgan Healthcare Conference to outline broader clinical plans, including the ECLIPSE Phase 3 program in hepatitis delta and...